Albendazole Deworming Regimens
For empirical deworming or common intestinal helminth infections in adults and children over 24 months, administer albendazole 400 mg as a single oral dose. 1
Standard Dosing by Infection Type
Single-Dose Regimens (400 mg)
The following infections respond well to a single 400 mg dose of albendazole:
- Ascariasis (roundworm): Single dose 400 mg 1
- Hookworm (Ancylostoma/Necator): Single dose 400 mg 1
- Pinworm (Enterobius): Single dose 400 mg, repeat in 2 weeks 1
- Empirical treatment for undiagnosed geohelminth infection: Single dose 400 mg (often combined with ivermectin 200 μg/kg) 1
Multi-Day Regimens
Hookworm infections requiring higher efficacy: Albendazole 400 mg daily for 3 consecutive days 1. This extended regimen achieves superior cure rates compared to single-dose treatment, particularly for Necator americanus.
Whipworm (Trichuris trichiura): Mebendazole 100 mg twice daily PLUS ivermectin 200 μg/kg once daily, both for 3 days 1. Note that albendazole alone shows suboptimal efficacy against Trichuris (cure rates ~48-50%) 1, 2, 3, making combination therapy preferable.
Trichinellosis:
- Mild disease: Albendazole 400 mg once daily for 3 days 4
- Severe disease: Albendazole 400 mg twice daily for 8-14 days plus prednisolone 40-60 mg daily 4
Cutaneous larva migrans: Albendazole 400 mg twice daily for 21 days 1
Visceral larva migrans (Toxocara): Albendazole 400 mg twice daily for 5 days 1
Age-Specific Considerations
Children 12-24 months: Discuss with an expert before empirical treatment 1. The standard 400 mg dose appears safe and effective in children aged 2-15 years based on extensive safety data 2, 5.
Infants under 12 months: Insufficient data; specialist consultation required.
Adults and elderly: Standard 400 mg dosing applies. Pharmacokinetic studies show similar drug handling across age groups up to 79 years 6.
Administration Guidelines
Take with food: Albendazole absorption increases up to 5-fold when administered with a fatty meal (approximately 40 grams of fat) 6. This significantly enhances systemic exposure to the active metabolite albendazole sulfoxide.
Tablet administration: Some patients, particularly children, may have difficulty swallowing tablets whole. The tablets can be crushed or chewed if necessary 6.
Pregnancy: Albendazole is contraindicated in pregnancy due to teratogenic effects demonstrated in animal studies 6. Pregnancy testing is recommended for females of reproductive potential before treatment, and effective contraception should be used during treatment and for 3 days after the final dose 6.
Lactation: Low concentrations appear in breast milk with no reported adverse effects on breastfed infants 6.
Important Caveats
Loiasis exclusion: Before administering ivermectin (often combined with albendazole for empirical treatment), exclude Loa loa infection in anyone who has traveled to endemic regions of Central/West Africa 1. Ivermectin can precipitate severe encephalopathy in patients with high Loa loa microfilarial loads.
Neurocysticercosis: For Taenia solium (pork tapeworm) intestinal infection, exclude neurocysticercosis before using praziquantel, as it may precipitate neurological complications 1. Niclosamide 2 g single dose is preferred for T. solium intestinal infection.
Efficacy limitations: While albendazole demonstrates excellent efficacy against Ascaris (95% cure rate) and hookworm (78-93% cure rate depending on species), its performance against Trichuris is notably lower (48-50% cure rate) 1, 2, 3. For heavy Trichuris infections, consider combination therapy with mebendazole plus ivermectin or triple-dose albendazole (400 mg daily for 3 days) 7, 8.
Repeat dosing for schistosomiasis: When treating empirically for possible schistosomiasis, repeat albendazole treatment at 8 weeks to target worms that have matured from eggs and schistosomulae that are relatively resistant to initial treatment 1.
Safety profile: Albendazole has an excellent safety record with over several hundred million patient exposures. Adverse effects are rare (<1% incidence), predominantly mild gastrointestinal symptoms (nausea, vomiting, abdominal pain) 2, 5. Mass administration studies show only 1.37 adverse events per 1000 recipients, all mild in nature 5.